Following rituximab treatment, people of African ancestry with immune thrombotic thrombocytopenic purpura (iTTP) experience a relapse significantly sooner than individuals with European ancestry, a…
HMB-002, an antibody-based experimental treatment for von Willebrand disease (VWD) currently in early clinical testing, boosted levels of the protein whose deficiency causes VWD, according to a new study in animal models. The study, “HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for…
Latest news & perspectives
Living with a rare disease often means feeling unseen and alone, even when surrounded by supportive family, friends, and a medical team. While they certainly…
